~//bj.watch/overview
live

entity dossier

Project Blueprint

Project Blueprint is bryan johnson's longevity protocol and commercial health platform. It began as an N=1 self-experiment: measure organ systems and biomarkers, choose interventions from literature and clinical practice, implement them with a medical team, then re-measure. Johnson's 2021 framing was explicitly system-oriented: his body would generate the “grocery shopping list,” and the core innovation was a feedback loop where organs and biomarkers outranked momentary preference.

productlongevitybiohackingbiomarkersprotocolhealth

// Habits · Longterm · Don’ts

Project Blueprint: habits, longterm, and don’ts

Three buckets keep practical routines, long-range interpretation, and source-aware caution visible on every protocol surface.

repeatable behaviors

Habits

  • Run the measurement loop: bloodwork, wearables, oral/skin/organ metrics, then retest instead of relying on vibes.concepts/blueprint-protocol.md
  • Keep the stable inputs visible first: consistent sleep, training, nutrient-dense meals, oral care, light exposure, and recovery.concepts/blueprint-protocol.md
durable strategy

Longterm

  • Treat Blueprint as a repeatable feedback system whose rules can evolve as biomarkers, symptoms, or evidence change.concepts/blueprint-protocol.md
  • Track the June 2026 sauna/HSP27 thread as a protocol-design case study: Johnson shifted the dose question from minutes in the sauna to measured core temperature and biomarker response.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
  • Treat the July 2026 sauna checklist as Johnson’s attributed protocol guidance. Its 4–7-session frequency, heat-dose targets, fertility and microplastics claims, hydration advice, and environmental cautions are not a reader prescription or independent evidence of longevity benefit.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
  • Track the June 2026 jet-lag follow-up as a self-reported caffeine + melatonin test using blood glucose as a body-clock readout, not as general travel medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md
  • Treat the June 2026 Australian sun/skin-aging post as a skin-readout example inside the measurement loop, not as validated skincare advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
  • Treat the June 2026 Immortals Rx expansion separately from foundational habits; the GLP-1, SGLT2, peptide, and NAD+ catalog is a commercial/protocol claim that requires clinician oversight.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
  • Treat the July 2026 six-option GLP-1 catalog as an Immortals Rx commercial update. Johnson names branded and compounded listings, but the post does not establish formulation status, availability, prescribing criteria, or safety and efficacy for longevity use.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
  • Treat Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence intervention claim. He identifies the cited work as preclinical and the human evidence as observational; his proposed extension from sildenafil to tadalafil is not evidence of efficacy or a reason to combine medicines.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
  • Treat Johnson’s June 2026 “one international trip per quarter” rule as a biomarker-derived personal boundary, not as a reader travel guideline.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
  • Treat the June 2026 inherited-cancer DNA + RNA panel as germline risk-stratification context, not a diagnosis, universal screening recommendation, or validation of Johnson’s early-surveillance statistics.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
  • Treat the July 2026 AIG single-cell immune-receptor sequencing thread as Johnson’s diagnostic follow-through: a cellular/receptor-level measurement layer, not a validated therapy or reader test recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
  • Treat the July 2026 low-ferritin / Monoferric follow-up as Johnson’s self-reported AIG case and false-negative philosophy, not a general iron-infusion recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
  • Treat the July 2026 AIG cure roadmap and “Bryan in a dish” model as a proposed personal experiment; it is not an approved autoimmune-disease cure, validated ex-vivo screening protocol, or reader treatment pathway.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
  • Treat the July 2026 Kate Tolo endometriosis workup as multi-modality diagnostic-triangulation context; it is not a reader diagnostic pathway, independent validation, or proof that endometriosis can now be cured.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
  • Read Johnson’s July 2026 “removing harm” list as a subtraction-first behavior philosophy. Sleep consistency, movement, avoiding nicotine/alcohol, and reducing obvious hazards belong with foundations; the post does not quantify each item or resolve the safety and attribution questions around his intervention stack.raw/articles/bryan-johnson/x-twitter-daily-2026-07-11.md
  • Treat the July 2026 Kate Tolo 90-day / 1,900-biomarker announcement as a projected N=1 program specification, not completed female-health evidence, a representative protocol, or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Treat Johnson’s RHR “Sovereignty Index” as within-person behavior-design framing. His reported 41 bpm average is not a universal target, and resting heart rate needs individual and clinical context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Treat the July 2026 ocular tear-panel post as an organ-specific measurement plan. Johnson reports a $1,800 specialty-lab panel across 15 biomarkers, but publishes no result, diagnosis, clinical utility, intervention, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
  • Treat Immortals’ July 2026 disease-resolution infrastructure expansion as Johnson’s strategy and product positioning. The iPSC, organoid, deep-cell-characterization, and personalized-therapy directions do not establish an operational clinical platform, diagnosis, treatment, cure, safety, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
  • Treat the July 2026 operational Kate Tolo baseline as an N=1 measurement program. The 100-day, 14-million-data-point plan with 100+ daily tasks, 50+ devices, and a 12-person team is not completed evidence, a representative female-health protocol, or reader guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
  • Treat Johnson’s August 2026 claim that Kate Tolo’s protocol was built in 90 days and is “better” than his five-year build as an operational comparison only. No quality criteria, comparative measurements, outcomes, or external validation were published.raw/articles/bryan-johnson/x-twitter-daily-2026-08-05.md
  • Treat Johnson’s August 2026 47-tube, 250 mL blood draw as a scale and methods update. The post names single-cell immune sequencing and broad measurement domains but publishes no assay list, results, diagnosis, clinical interpretation, or evidence that collection volume improves outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-08-13.md
  • Treat Johnson’s August 2026 interval-training post as an attributed exercise claim, not a prescription. The 4×4 shape (3 sessions/week, 4 minutes at 90–95% effort with 3 easy minutes, 8 weeks) is the Helgerud et al. 2007 protocol (+7.2% VO2max), and the “11% lower all-cause mortality” figure compresses per-MET fitness associations (Kodama et al. 2009: 13% lower all-cause mortality per MET, RR 0.87)—no trial has measured mortality from eight weeks of intervals, and the post names no study.https://x.com/bryan_johnson/status/2092230490581574033
  • Treat Johnson’s August 2026 LDL post as an attributed cholesterol claim. The “49 trials, 312,175 people, ~23% fewer major vascular events per 39 mg/dL” figure matches Sabatine et al. 2016 (JAMA; RR 0.77 per 1 mmol/L), and the “13–14% over six months” diet figure matches the Jenkins et al. 2011 portfolio-diet RCT (−13.1% to −13.8% LDL from viscous fiber, nuts, plant protein, and plant sterols)—but the post names neither study, and trial-population relative effects are not individual guarantees or a lab-interpretation directive.https://x.com/bryan_johnson/status/2092597711543632216
  • Treat Johnson’s August 2026 NTE-by-age decline tables as an attributed normative-data claim. The age-related decline is documented (Karacan et al. 1975 normative NPT series; Schiavi et al. 1988; Horita & Kumamoto 1989: 189.6 min at age 20 declining to ~62 min at 70, nearly matching his age-20 anchor), but the post names no study, its intermediate bins match no single published cohort, and the repeated “2x risk in 4 years” outruns meta-analytic averages—not a validated risk prediction or monitoring recommendation.https://x.com/bryan_johnson/status/2093698799172829255
  • Treat Johnson’s August 2026 Kernel brain-scan percentile post as an attributed self-report. The regional percentiles (amygdala 95th, putamen 99th, caudate 97th, frontal gray matter 78th “and climbing”), heritability figures, and personality mappings are his own account against an undisclosed normative cohort; the plasticity literature he gestures at (Draganski et al. 2004: transient visual-motion-cortex gray-matter change from juggling; Colcombe et al. 2006: frontal-volume gains from aerobic exercise in older adults) does not validate region-by-region self-interpretation—not a brain-health metric, evidence the protocol grew his frontal cortex, or medical advice.https://x.com/bryan_johnson/status/2094112145357291863
  • Treat Johnson’s August 2026 nighttime-erection post as an attributed N=1 biomarker claim. ED does precede and predict cardiovascular events (Vlachopoulos et al. 2011 JACC meta-analysis: RR 1.48 CVD, 1.35 stroke; Krimpen cohort: HR 2.6 only for severely reduced rigidity), but his flat “2x risk in 4 years” outruns the meta-analytic averages, the post names no study, consumer NTE scores are not a validated clinical risk tool, and daily tadalafil 5 mg is a prescription medication requiring clinician oversight—not a reader protocol.https://x.com/bryan_johnson/status/2093061998468903267
  • Treat the Baseten biological-age event as public measurement positioning. Its brain, skin, strength, balance, reaction-speed, and mobility domains are not evidence that the tests form a validated or actionable biological-age score.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
  • Treat the August 2026 meibomian-gland post as an attributed N=1 diagnosis-and-intervention account. Johnson reports advanced MGD with gland dropout, a four-therapy stack (IPL, radiofrequency, intraductal probing, 630nm red light), and a self-reported 30% gland-function improvement; his own post says the probing science is unsettled and the therapies cannot be separated. It is not a validated eye-care protocol or reader guidance.https://x.com/bryan_johnson/status/2089822905891000605
  • Preserve medical-caution framing: this page summarizes Johnson/Blueprint practice, not personal treatment advice.concepts/biomarker-driven-longevity-protocols.md
guardrails

Don’ts

  • Do not present N=1 biomarker movement as proof of clinical outcomes.concepts/biomarker-driven-longevity-protocols.md
  • Do not mix experimental drugs, hormones, or supplements into the same confidence tier as sleep, exercise, and food quality.concepts/blueprint-protocol.md

Project Blueprint

Project Blueprint is bryan johnson’s longevity protocol and commercial health platform. It began as an N=1 self-experiment: measure organ systems and biomarkers, choose interventions from literature and clinical practice, implement them with a medical team, then re-measure. Johnson’s 2021 framing was explicitly system-oriented: his body would generate the “grocery shopping list,” and the core innovation was a feedback loop where organs and biomarkers outranked momentary preference.

By 2026, Blueprint had expanded into a public “Protocol Marketplace,” supplements/foods/skincare, certified products, biomarker testing, an AI health companion, and user-facing protocol personalization. The biomarker page advertises urine and blood testing, 100+ biomarkers, 160+ measurements per year, past-lab import, six-month retesting, and AI-generated evidence-backed protocol guidance.

Methodology

The methodology is a closed-loop optimization system:

  1. Define a health/longevity target, often in terms of biological age, organ age, or speed of aging.
  2. Measure extensively: blood/urine biomarkers, imaging, functional tests, wearable data, and epigenetic clocks.
  3. Choose interventions using scientific literature, clinical practice, and self-experimentation.
  4. Run the protocol with discipline: diet, sleep, exercise, supplements, prescriptions, devices, imaging, and occasional experimental therapies.
  5. Re-measure, drop failures, iterate.

This makes Blueprint a concrete example of biomarker driven longevity protocols: the decision system is the product, not just any one food, supplement, or device.

Claimed benefits and accessible core

Johnson’s protocol materials emphasize simple, repeatable behaviors as well as expensive testing: lower resting heart rate before bed, keep a consistent bedtime, stop food several hours before sleep, avoid evening screens, exercise, and measure progress. His X/Twitter posts in May 2026 repeatedly returned to sleep timing, RHR, sauna, vaccines, peptides, and the idea that “biomarkers in context” are more useful than raw measurement.

Commercialization

Blueprint has become a product ecosystem. Its site offers protocols and products by benefit area (daily health/longevity, brain/heart, energy/stress, muscle/recovery, nutrition, gut/immune, hair/skin), and claims its products are built on population-level studies, tested, and certified. Biomarkers membership is positioned as a lower-cost way to bring Johnson’s “scientific framework” to users.

Limits and critiques

The core scientific limitation is N=1: Johnson changed many variables simultaneously, with no control group, making causal attribution impossible. YEARS emphasizes that data volume and clinical relevance are different; epigenetic clocks are predictors, not proof that a lower score adds healthy years. MDLinx similarly notes that some elements (sleep, exercise, some monitoring) have support, while other aspects — 100+ supplements, extensive imaging, off-label/experimental interventions — may not be generalizable or necessary.

The practical takeaway is to separate Blueprint into layers: evidence-backed basics (sleep, exercise, nutrition, clinically indicated testing), data-driven personalization, commercial products, and experimental/medical interventions. The first two are broadly useful concepts; the latter two require stronger skepticism, medical supervision, and conflict-of-interest awareness.